EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Etoposide, Topoisomerase II and Cancer

E L Baldwin, N Osheroff

Current Medicinal Chemistry-Anti-Cancer Agents · 01.07.2005 · 5 (4) · 363-372

DOI: 10.2174/1568011054222364 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Medicinal Chemistry-Anti-Cancer Agents, erschienen am 01.07.2005. Verfasst von E L Baldwin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, 654 Robinson Research Building, Vanderbilt University School of Medicine, Nashville, TN 37232-0146, USA. Die Arbeit wurde bisher 441-mal zitiert (Crossref). Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Etoposide is an important chemotherapeutic agent that is used to treat a wide spectrum of human cancers. It has been in clinical use for more than two decades and remains one of the most highly prescribed anticancer drugs in the world. The primary cytotoxic target for etoposide is topoisomerase II. This ubiquitous enzyme regulates DNA under- and overwinding, and removes knots and tangles from the genome by generating transient double-stranded breaks in the double helix. Etoposide kills cells by stabilizing a covalent enzyme-cleaved DNA complex (known as the cleavage complex) that is a transient intermediate in the catalytic cycle of topoisomerase II. The accumulation of cleavage complexes in treated cells leads to the generation of permanent DNA strand breaks, which trigger recombination/repair pathways, mutagenesis, and chromosomal translocations. If these breaks overwhelm the cell, they can initiate death pathways. Thus, etoposide converts topoisomerase II from an essential enzyme to a potent cellular toxin that fragments the genome. Although the topoisomerase II-DNA cleavage complex is an important target for cancer chemotherapy, there also is evidence that topoisomerase II-mediated DNA strand breaks induced by etoposide and other agents can trigger chromosomal translocations that lead to specific types of leukemia. Given the central role of topoisomerase II in both the cure and initiation of human cancers, it is imperative to further understand the mechanism by which the enzyme cleaves and rejoins the double helix and the process by which etoposide and other anticancer drugs alter topoisomerase II function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsDNA DamageDNA Topoisomerases, Type IIEtoposideHumansNeoplasmsStructure-Activity RelationshipTopoisomerase II Inhibitors

Substanzen

Topoisomerase II InhibitorsEtoposideDNA Topoisomerases, Type II

Autor:innen und Institutionen

  • Department of Biochemistry, 654 Robinson Research Building, Vanderbilt University School of Medicine, Nashville, TN 37232-0146, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Baldwin, E. L., & Osheroff, N. (2005). Etoposide, Topoisomerase II and Cancer. Current Medicinal Chemistry-Anti-Cancer Agents, 5(4), 363-372. https://doi.org/10.2174/1568011054222364

Vancouver

Baldwin EL, Osheroff N. Etoposide, Topoisomerase II and Cancer. Current Medicinal Chemistry-Anti-Cancer Agents. 2005;5(4):363-372. doi:10.2174/1568011054222364

BibTeX
@article{Baldwin2005,
  author = {Baldwin, E L and Osheroff, N},
  title = {Etoposide, Topoisomerase II and Cancer},
  journal = {Current Medicinal Chemistry-Anti-Cancer Agents},
  year = {2005},
  volume = {5},
  number = {4},
  pages = {363--372},
  doi = {10.2174/1568011054222364}
}
Kostenlos starten →